Industry Supported Symposium

APASL STC Osaka 2021 Program of Sponsored Seminars

Day 1: September 2nd (Thursday) 2021
12:40-13:40 (JST)

Luncheon Seminar 1: Sponsored by Eisai Co. Ltd. / MSD K.K.

Chair: Junji Furuse (Japan)
Consideration of the Decision Process of Treatment in Patients with Hepatocellular Carcinoma
Dr. Sadahisa Ogasawara (Japan)
Clinical Outcome of Lenvatinib Therapy in Japanese Patients with Unresectable HCC
Dr. Kaoru Tsuchiya (Japan)
18:50-19:50 (JST)

Evening Seminar 1: Sponsored by Chugai Pharmaceutical Co., Ltd.

Chair: Dr. Kiyoshi Hasegawa (Japan)
A New Era of Cancer Immunotherapy in Hepatocellular Carcinoma
Dr. Masatoshi Kudo (Japan)
Day 2: September 3rd (Friday) 2021
8:00-9:00 (JST)

Morning Seminar: Sponsored by Otsuka Pharmaceutical Co., Ltd.

Chair: Dr. Hitoshi Yoshiji (Japan)
Management of Liver Cirrhosis: Summary of JSGE & JSH Evidence-based Clinical Practice Guidelines for Liver Cirrhosis 2020
Dr. Naoya kato (Japan)
13:10-14:10 (JST)

Luncheon Seminar 2: Sponsored by AbbVie GK

Chair: Tatehiro Kagawa (Japan)
Clinical Outcome of Antiviral Therapy in Patients with Hepatitis C Virus Infection
Dr. Toshifumi Tada (Japan)
Hepatocellular Carcinoma Developing after the Eradication of Hepatitis C Virus: Surveillance, Characteristics, and Prognosis
Dr. Hidenori Toyoda (Japan)
18:40-19:40 (JST)

Evening Seminar 2: Sponsored by Gilead Sciences K.K.

Chair: Dr. Yasuhito Tanaka (Japan)
Novel Agents for HBV Therapy
Dr. Man-Fung Yuen (Hong Kong, China)